Sutro Q2 revenue drops to $9.8M from $63.7M; STRO-004 shows early responses

SUTRO BIOPHARMA, INC.

Revenue $9.8M vs $63.7M in Q2 2025; cash $164.3M vs $202.6M at March 31, 2026.
STRO-004 Phase 1: confirmed and unconfirmed partial responses in pancreatic, head/neck, NSCLC at 3-4 mg/kg; discontinuation rate 6%.
STRO-004 PK: half-life ~7 days, DAR8 preserved, 25-50% more ADC exposure with 50% less payload vs conventional.
STRO-006 Phase 1 start expected Q3 2026; STRO-227 IND on track for 2026.
Astellas collaboration: $10M milestone received April 2026; second iADC program to enter clinic by end 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.